 RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2020 GLOBE NEWSWIRE -- G1 Therapeutics, Inc. Nasdaq: GTHX, a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present company updates at two investor conferences in August 2020: BTIG Virtual Biotechnology Conference 2020 on Monday, August 10, 2020 at 11:30 a.m. ET 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 10:55 a.m. ETTo access live and archived webcasts of the presentations, please visit the Events Presentations page of the G1 website.About G1 Therapeutics G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class FDA-designated Breakthrough Therapy designed to improve outcomes for patients being treated with chemotherapy. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader SERD for the treatment of ER breast cancer. Lerociclib is a differentiated oral CDK46 inhibitor designed to enable more effective combination treatment strategies.G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit and follow us on Twitter G1Therapeutics.Contact: Jeff Macdonald G1 Therapeutics, Inc. Senior Director, Investor Relations Corporate Communications 919-907-1944 